FDA Approves Dupilumab for Chronic Spontaneous Urticaria
Key Points: 1. FDA approves Dupixent as the first new CSU treatment in over a decade. 2. Phase 3 trial ...
Key Points: 1. FDA approves Dupixent as the first new CSU treatment in over a decade. 2. Phase 3 trial ...
1. In this phase 1 randomized controlled trial, urticaria was reported in several participants who received a messenger RNA vaccine ...
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be ...
1. In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on second-generation ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.